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1. Introduction 
Hepatocellular carcinoma (HCC) is one of the most common and rapidly fatal malignancies 
worldwide and has been ranked the second highest cancer killer in China since the 1990s, 
particularly in the eastern and southern areas, including the inshore area of the Yangtze 
River (1). Multiple risk factors are associated with HCC disease etiology, with the highest 
incidence in patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV), 
although other factors such as genetic makeup and environmental exposure are involved 
(2~4). As a common malignant, solid tumor, HCC is characterized by fast infiltrating 
growth, early metastasis, high-grade malignancy, and poor therapeutic efficacy. It is a 
highly vascular tumor dependent on neovascularization and one of the most common and 
rapidly developing malignancies (5, 6). HCC treatment options are severely limited by the 
frequent presence of metastases (7～10, Fig.1).  
Multistep malignance of HCC progression with multigene alterations mostly accompany 
with chronic hepatitis and liver cirrhosis (11, 12). Hypoxia inducible factor-1 (HIF-1) is a 
basic-Helix–Loop–Helix Per-Arnt-Sim protein (bHLH-PAS) consisting of ǂ and ǃ subunits 
and a key transcription factor regulating cellular responses to hypoxia (13, 14), and can 
regulate neovascularization, activate expressions of many hypoxia-response genes, leading 
to closely associate with HCC ecosystem for tumor growth, infiltration, metastasis and 
prognosis (15~17). HIF-1ǂ is an oxygen-dependent protein, which is degraded by poly 
ubiquitination and proteasomal degradation via the Von-Hippel-Lindau tumor suppressor 
protein under normoxic conditions (4, 18, 19). Here we briefly review the expression of rat 
hepatic HIF-1ǂ and its gene during the malignant transformation of hepatocytes, the hepatic 
expression and circulating level of HIF-1ǂ in patients with liver diseases for prospectively 
elucidating the relationship between HIF-1ǂ level and the pathological features as well as 
the diagnosis and metastasis of HCC, and the effect of miRNA silencing HIF-1ǂ gene on 
inhibition of HepG2 cell proliferation. 
2. HIF-1alpha expression and HCC development 
Hepatocarcinogenesis is a complex process requiring multiple factors and multiple steps. 
Chemical carcinogens can induce cancer development in liver cells in a short time, with 
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Fig. 1. HCC development and the role of hepatic HIF-1ǂ. A, Model for the development of 
hepatocyte malignant transformation and the role of HIF-1ǂ during liver tumorigenesis. The 
gradual replacement of cells during normal physiologic turnover is accomplished by the 
proliferation of the differentiated liver cells, in response to various forms of liver injury to 
canceration. In contrast, when parenchymal cells are unable to proliferate (e.g., in response 
to hepatocyte toxins), rare cells associated with the bile ducts known as oval cells expand 
and then differentiate to restore liver mass. The alterations of many genes result in 
hepatocyte and oval cell proliferation and the development of HCC. B, The role of hepatic 
HIF-1ǂ. Regulation of the ǂ-subunit is mediated by the oxygen dependent degradation 
domain (ODD), which contains two regulatory proline residues. Transcriptional activity of 
HIF-1 is facilitated by a N- vs. C-terminal transactivation domains (TAD-N vs. TAD-C) in 
HIF-1ǂ. B1, Under normoxia O2 is available and hydroxylation via FIH-1 and PHDs 
proceeds. FIH-1 hydroxylates Asn 803 in the C-TAD of HIF-1ǂ. This modification causes 
CBP/p300 to dissociate from HIF-1ǂ, thus repressing HIF-1 transcriptional activity. PHDs 
hydroxylate Pro 402 and Pro 564 within the ODD of HIF-1ǂ thereby making it available for 
the binding of pVHL. pVHL forms a E3-ubiquitin ligase complex with co-factors which 
subsequently facilitates poly-ubiquitination of HIF-1ǂ and thus degradation by the 26S 
proteasome. B2, Scheme of the proposed role of HBx in the HIF-1-mediated angiogenesis of 
HCC. HBx interacts and stabilizes HIF-1 through inhibition of the interaction between 
pVHL and HIF-1 and the ubiquitin (Ub)-dependent degradation. Subsequently, HBx 
activates the HIF-1-dependent transcription and leads to angiogenesis. Under hypoxia O2 is 
limited and PHDs as well as FIH are inactive. In turn HIF-1ǂ accumulates associates with 
the ǃ-subunit and upon recruitment of the co-factor p300 forms the transcriptionally active 
HIF-1 complex. Activation of genes that contain HIF-responsive elements (HRE) in their 
promotor region follows 
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large-scale RNA transcription. The total RNA content gradually increases, and in the 
precancerous lesion, this can be significantly different from normal tissues. Angiogenesis is 
necessary for solid tumors larger than 1×1 mm, or the tumor remains dormant and does not 
metastasize. As soon as the angiogenesis stage arrives, potent metastasis is exhibited at once. 
The expression of HIF-1ǂ plays important roles in angiogenesis, tumor growth, invasion, 
and metastasis in different cancers. We have investigated the expression of HIF-1ǂ and its 
gene at the early stage of hepatocarcinogenesis, and provided the first evidence to show that 
HIF-1ǂ is activated in preneoplastic hepatocytes during the early stage of carcinogenesis 
and long before the development of HCC.  
 
 
Fig. 2. Appearance of rat liver and morphological changes of rat hepatocytes during 2-FAA-
induced hepatocarcinogenesis. A-D: liver appearance of control rats, at the early, middle, 
and late stages during the malignant transformation of hepatocytes ; E-H: corresponding 
histopathological images confirming normal tissue, hepatocyte degeneration, precancerous, 
changes and HCC (original magnification ×100), respectively.  
Forty-eight male Sprague-Dawley rats, 6 weeks old, weighing 150-160 g, were purchased 
from the Experimental Animal Center, Nantong University, China. All animals were treated 
according to the guidelines of Nantong University for the Care and Use of Laboratory 
Animals. The rats were randomly divided into 8 groups with 6 rats per cage. One group was 
selected as controls while the others made up the experimental groups. Among the 7 
experimental groups one served as a substitute for accidental deaths. All rats were fed with 
general grain, except that the grain of the hepatoma model rats contained 0.05% 2-fluorenyl-
acetamide (2-FAA, Sigma Chemical Co., USA). All rats were housed under bio-clean 
conditions. One control rat and one experimental rat were sacrificed every 2 weeks. All 
surgical procedures were conducted under deep ether anesthesia. Four ml of blood was 
drawn from the heart and anticoagulated with EDTA-K2. Plasma and karyocytes were 
separated and kept at -80 ℃ for further analysis. After washing off the blood, one liver 
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sample was fixed in 10% neutral buffered formalin and embedded in paraffin for 
pathological examination and immunohistochemical staining, and the rest were kept at -80 ℃ until use. 
The changes of liver appearance and the pathohistology of hepatocytes during 2-FAA-
induced rat HCC development are shown in Fig. 2. Apparent morphological changes (Fig. 
2A-D) were confirmed pathohistologically examination (Fig. 2E-H). No pathological 
changes of rat hepatocytes were found in normal controls (Fig. 2E). During 2-FAA-induced 
hepatocarcinogenesis, granule-like degeneration in the cytoplasm of hepatocytes occurred at 
the early stage of hepatocarcinogenesis, with a few large and dysmorphic nuclei 
(degeneration group, n=18, Fig. 2F). An increase in the number of cell layers of hepatic 
plates was observed at the middle stage, at which there were more than 3 cell layers in some 
foci. Thickened chromatin in the nucleus was found, and the ratio of nucleus versus 
cytoplasm was elevated (precancerous group, n=9, Fig. 2G). At the late stage, the normal 
structure of liver tissue was completely destroyed, hepatocytes were rearranged to be nest-
like and crudely cord-like, cellular nuclei were moderate in size and chromatinthickened, 
the ratio of nucleus versus cytoplasm was elevated, and the liver tissues were confirmed as 
highly differentiated (cancerous group, n=9, Fig. 2H). 
Immunohistochemical staining confirmed positive expression of HIF-1ǂ as clear and brown 
particles, mainly located in the cytosol and nuclei, with no staining of the plasma membrane 
(Fig. 3). The positive staining was mostly located in the border of hepatic terminal portal 
venules or near the central veins (Fig. 2A). With carcinogenesis, the rate of HIF-1ǂ-positive 
expression increased and there was significantly higher intensity in the degeneration, 
precancerous, and cancerous groups than in the normal control (Table 1, P < 0.05), with a 
dynamically changing HIF-1ǂ expression intensity. 
 
 
 
Fig. 3. Immunohistochemical staining with anti-HIF-1ǂ in rat HCC. A: HIF-1ǂ-positive 
expression in cytoplasm and cell membrane (S-P, original magnification ×200) in HCC focus 
from rat hepatoma; B: HIF-1ǂ-negative expression, brown particles in cytoplasm and cell 
membrane (S-P, original magnification ×200) in control rats. 
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    Intensity of HIF-1ǂ 
Group  n Positive (%)     
    - + ++ +++ 
Control  6 0 (0.0) 6 0 0 0 
Degeneration  18 14(77.8) 4 9 5 0 
Precancerous  9 8(88.9)* 1 2 5 1 
Cancerous  9 9(100)* 0 1 2 6 
<0.01, compared with the control group. 
Table 1. Comparative analysis of hepatic HIF-1ǂ expression intensity at different stages of 
rat hepatocarcinogenesis 
Reverse-transcribed HIF-1ǂ cDNA from hepatic HIF-1ǂ mRNA during the malignant 
alteration of rat hepatocytes was amplified by nested-PCR, and the sizes of amplified 
fragments were identical to the original designed ones, i.e., the size of the PCR product was 
500 bp in the 1st PCR and 210 bp in the 2nd PCR (Fig. 4). The amplified fragments (210 bp) 
of the rat HIF-1ǂ gene from the degeneration, the precancerous, and the cancerous livers 
were purified and confirmed by DNA sequencing. The alignments of their nucleotide 
sequences at the different stages of hepatocarcinogenesis by sequencing, and no alteration of 
the amplified gene fragment was found during the malignant alteration of rat hepatocytes. 
 
 
Fig. 4. Amplification and alteration of HIF-1ǂ gene from rat hepatoma tissues. In order to 
obverse the alteration of HIF-1ǂ at RNA level, HIF-1ǂ mRNAs were synthesized to HIF-1ǂ 
cDNA with random hexamers and moloney murine leukemia virus reverse-transcriptase, 
and detected with different primer pairs by nested PCR (210bp). The amplified positive 
fragments of HIF-1ǂ gene were distinctly found in rat hepatoma tissues. HIF-1ǂ mRNA in 
rat liver (Lanes. 1-4). Lane 1: control rat; lane 2: Degeneration rat; lane 3: precancerous rat; 
lane 4: HCC rat; marker: DNA molecular weight marker. 
The levels of total RNA and HIF-1ǂ mRNA expression in rat liver tissues during the 
malignant alteration of hepatocytes are shown in Table 2. The expression of total RNA and 
HIF-1ǂ mRNA with histological alteration of hepatocytes was observed in the rats after 
treatment with 2-FAA, progressing from granule-like degeneration to precancerous lesions 
to HCC. The levels increased markedly in the cancerous group and the precancerous lesion 
group, and the incidence of amplified HIF-1ǂ mRNA dynamically increased as hepatocytes 
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changed from normal to granule-like denaturation to precancerous and cancerous lesions. 
Induction of HIF-1ǂ mRNA expression was detected in all the liver tissues of the cancerous 
group and parts of the precancerous lesion and degeneration group, i.e., 44.4% in the 
hepatocyte degeneration group, 77.8% in the precancerous lesion group, and 88.9% in the 
HCC group. It was significantly higher in the cancerous group than in the degeneration and 
the control groups, and the precancerous lesion group was also significantly higher than the 
normal control. 
 
Group n Total RNA (μg/mg liver) HIF-1ǂ mRNA (%) 
Control 6 1.58±0.49 0 (0.0) 
Degeneration 18 1.91±0.60 8 (44.4) 
Precancerous 9 2.00±0.21* 7 (77.8)* 
Cancerous 9 2.86±0.60* 8 (88.9)* 
*P<0.05, compared with the control group. 
Table 2. Dynamic alterations of total RNA and amplification of HIF-1ǂ mRNA in liver 
tissues at different stages of rat hepatocarcinogenesis 
Nested PCR results revealed that HIF-1ǂ mRNA was induced in hepatoma, precancerous 
and degenerative tissues, but was not expressed in normal tissues. During the course of 
cancer development, the levels of HIF1ǂ mRNA in precancerous tissues were higher than in 
normal and degenerating tissues, and the levels of HIF-1ǂ mRNA in HCC tissues were even 
higher than in precancerous tissues. The activation of HIF-1ǂ gene transcription may 
participate in the signal transmission of cancer development. In the early stage, the 
expression of HIF-1ǂ mRNA and HIF-1ǂ was at low levels. In the advanced stage of cancer 
development, the expression of HIF-1ǂ mRNA and HIF-1ǂ was at high levels. The 
preneoplastic hepatic lesions showed increased levels of HIF-1ǂ and HIF-1ǂ mRNA 
compared with the normal liver. So the upregulation of hepatic HIF-1ǂ protein synthesis 
and HIF-1ǂ mRNA levels strongly suggest that HIF-1ǂ participates in the development of 
HCC. The expression of HIF-1ǂ gradually increased along with the histological changes, it 
was significantly higher in premalignant tissues than in the control group, and it may be 
related to the activation of signal pathways. 
The quantitative data of hepatic and circulating HIF-1ǂ expression are shown in Table 3. 
The HIF-1ǂ levels showed a tendency to increase with the histopathological changes: 
cancerous group > precancerous lesion group > hepatocyte degeneration group > control 
group. The levels were markedly higher in the cancerous and precancerous lesion groups 
than in the hepatocyte degeneration and normal control groups. As a result of its low 
molecular weight, HIF-1ǂ is easily released into the blood, leading to a higher concentration 
there. Blood levels in the precancerous lesion group were higher than in the hepatocyte 
degeneration and normal control groups (P<0.05). The HIF-1ǂ blood levels in the cancerous 
group were markedly higher than in any other group (P<0.05). An apparent positive 
correlation between the levels in blood and liver samples was found (r=0.474, P = 0.030). The 
expression level of HIF-1ǂ gradually increased both in liver cells and blood. The increasing 
tendency of hepatic and circulating HIF-1ǂ was synchronized, suggesting that the 
increasing expression of HIF-1ǂ is closely related to the malignant transformation of 
hepatocytes.  
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Group n HIF-1ǂ in blood (μg/mg NP) HIF-1ǂ in liver (μg/mg) 
Control 6 206.3±18.6 9.8±2.9 
Degeneration 18 277.2±96.1 12.6±3.2 
Precancerous  9 401.6±178.8* 16.9±2.2* 
Cancerous 9 445.9±138.9* 23.5±8.7* 
*P<0.05, compared with the control group. 
Table 3. Quantitative analysis of HIF-1ǂ dynamic expression in circulation and liver tissues 
at different stages of rat hepatocarcinogenesis 
Increasing evidence suggests that HIF-1 activation occurs in the early stages of 
carcinogenesis. HIF-1ǂ genes are overexpressed in morphologically normal single cells, 
forming multicellular foci or microcysts similar to overt HCC. HIF-1ǂ was also shown to be 
expressed in a few cells in ductal hyperplastic areas adjacent to invasive cancer, and their 
malignant counterparts. Furthermore, HIF-1ǂ genes were shown to be overexpressed in 
hyperplastic and dysplastic lesions during multistage carcinogenesis. Recent new findings 
from several laboratories have implicated constitutive activation of the transcription factor 
NF-κB as one of the early key events involved in neoplastic progression of chronic liver 
disease. Further studies will permit us to analyze mechanism of human 
hepatocarcinogenesis and to know how to target HIF-1ǂ sites or RNA interference-mediated 
suppression of HIF-1ǂ expression for HCC therapy. However, the combination of the 
pathological features of HIF-1ǂ expression and some of the biomarkers with high sensitivity 
and specificity for early HCC seems to be more practical so far. 
3. Expression difference in human HCC tissues 
The self-controlled HCC and para-cancerous specimens (2 cm to cancer) were collected from 
35 patients who underwent operations for liver cancer at the Affiliated Hospital of Nantong 
University. The specimens were immediately frozen in liquid nitrogen and kept at –85℃ 
until required. The patients included 28 men and 7 women, ranging in age from 22 to 70 
years. Prior written informed consent was obtained from all patients according to the World 
Medical Association Declaration of Helsinki, and the study received ethics board approval 
from the Affiliated Hospital of Nantong University. The histological types of all HCC 
specimens were graded in differentiation degrees as follows: well, 9; moderate, 12; and poor, 
14. Of these specimens, 20 showed single tumor tubercles and the rest multiple; 14 were 
stage II, 13 were stage III, and 8 were stage IV. Each specimen was analyzed by total RNA 
abstraction and pathologic examination. 
The expressions and cellular distribution of HIF-1ǂ in HCC tissues and comparative 
analysis with their para-cancerous tissues are shown in Fig. 5. The positive HIF-1ǂ was 
brown and granule-like, mainly presented in cytoplasm and few in nucleus, with obvious 
differences of HIF-1ǂ positive expression intensity among different areas of tissues. HIF-1ǂ 
staining in paracancerous tissues was showing significantly in the compressed hepatic cords 
and central veins. The intensity of HIF-1ǂ expressions was significantly higher in 
paracancerous tissues than that in HCC, mainly due to more necrosis in the latter, 
representing that there is a very close relationship between high intensity of HIF-1ǂ 
expressions and active proliferation or hypoxia microenvironment in paracancerous tissues. 
The distribution of positive cells was well-distributed and higher in adjacent areas of 
necrosis and tumor infiltration in HCC (Fig.5A), whereas it was showing significantly in the 
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compressed hepatic cords and the border of central veins in the para-cancerous tissues 
(Fig.5B). Moreover, the HIF-1ǂ positive staining was significantly higher (P=0.017) in the 
para- cancerous group (100%, 35 of 35) than in the corresponding HCC group (80%, 28 of 
35). The intensity of hepatic HIF-1ǂ expression was also higher in the para-cancerous tissues 
than in the HCC tissues (Z =4.728, P< 0.001, Table 4). 
 
 
Fig. 5. Immunohistochemical staining of HIF-1ǂ, total RNA levels and amplification of HIF-
1ǂ mRNA in HCC or their paracancerous tissues. Hepatic HIF-1ǂ expression with brown 
particles in cytoplasm and cell membrane，A, the HCC tissue; B, the para-cancerous tissue 
(S-P, original magnification × 200). C, the levels of total RNA expression in HCC or their 
paracancerous tissues; D, the HIF-1ǂ mRNA was synthesized to HIF-1ǂ cDNA and 
amplified by nested PCR (349 bp), Line 1, 2, the amplified fragment of HIF-1ǂmRNA in 
HCC tissues; Line 3, 4, the amplified fragment of HIF-1ǂmRNA in para-cancerous tissues; 
M, DNA marker with molecular weight standard. HCC, the hepatocellular carcinoma 
tissues; Para-HCC, the para-cancerous tissues. 
HCC is mostly characterized by uncontrolled growth of tumor cells. Increasing oxygen 
consumption results in hypoxic microenvironment. HIF-1ǂ expression is significantly high 
in adjacent areas of necrosis and tumor infiltration. Many factors, such as hypoxia, 
oncogenes activation, inactivation of tumor suppressors, growth factors, inflammatory 
factors, can up-regulate HIF-1ǂ expressions, directly or indirectly promoting more than 2 % 
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human genes transcriptions, which are all related to oxygen and energy metabolism. 
Productive nucleic acids metabolism, abnormal gene expressions, development of HCC are 
closely associated with surrounding vessels state and hypoxic conditions (20).  
 
    HIF-1ǂ intensity 
Group n Positive (％) P value*    Z value P value* 
    － ＋ ＋＋ ＋＋＋   
HCC 35 28 (80.0) 0.017 7 21 7 0 4.728 0.000 
Para-HCC  35 35 (100)  0 10 18 7   
*P value vs the paracancerous tissue group; HCC, the hepatocellular carcinoma tissues. 
Table 4. The comparative analysis of HIF-1ǂ expression intensity in HCC or their 
paracancerous tissues 
 
 
Fig. 6. Alignment of the amplified fragments of HIF-1ǂ gene and homology analysis of their 
sequences. The HIF-1ǂ mRNA from cancerous tissue and para-cancerous tissue of HCC 
patients was synthesized to HIF-1ǂ cDNA and amplified by nested PCR (349 bp) and 
confirmed by sequencing. No mutation was found between HCC tissues and para-cancerous 
tissue. HIF-1ǂ: the cited sequence (349 bp, nt 2452-2800) of human HIF-1ǂ genome 
(NM_001530); HCC, the amplified fragment of HIF-1ǂ genome from HCC tissues; Para-
HCC, the amplified fragment of HIF-1ǂ genome from their paracancerous tissues. 
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Hepatic total RNA was purified from human HCC or their para- cancerous tissues, the 
specific concentrations of total RNA were 12.4 ± 7.3 μg/mg wet liver in the HCC group, and 
53.8 ± 52.0 μg/mg wet liver in the para-cancerous group (Fig.5C), with significant difference 
between them (t = 3.05, P < 0.01). The final amplified fragment of hepatic HIF-1ǂ gene was 
349 bp (Fig.5D), and the incidence was 85.7% in the HCC group and 100 % in the para-
cancerous group (P > 0.05). The amplified fragments of HIF-1ǂ gene were confirmed by 
sequencing, with consistent completely with the cited sequence of human HIF-1ǂ gene 
(Fig.6). The level of total RNA was obviously higher in paracancerous tissues than in HCC, 
indicating HIF-1ǂmRNA involved in cell proliferation, neovascularization and metastasis 
and could be a prime target for gene therapy. 
4. Expression of circulating HIF-1α in HCC 
One hundred thirty-one of HCC patients, 30 of chronic hepatitis, 22 of acute hepatitis, and 
37 of cirrhosis were diagnosed at the Affiliated Hospital of Nantong University, Nantong, 
China, and 27 healthy people obtained from the Nantong Central Blood Bank as controls 
(Table 5). All cases were diagnosed by blood biochemical tests, with negative hepatitis viral 
markers (HBsAg, and anti–HCV antibody), normal alanine aminotransferase (ALT) levels, 
and B-ultrasonic examination. All samples (5 mL of peripheral blood) were collected in the 
morning and sera were separated at once. The serum AFP concentrations exceeded 50 μg/L 
were taken as a positive result. The diagnosis of HCC and viral hepatitis was based on the 
criteria proposed by Chinese National Collaborative Cancer Research Group (21) and at the 
Chinese National Viral Hepatitis Meeting (22), respectively.  
 
Group n 
Sex 
M/F 
Age 
(Year) 
HBsAg 
(+/-) 
AFP (μg/L) 
≤20 21-399 ≥400 
HCC 
LC 
CH 
AH 
NC 
131 
37 
30 
22 
27 
109/22 
16/21 
25/5 
17/5 
12/15 
33-85 
20-82 
18-63 
24-80 
26-69 
100/31 
23/14 
22/8 
10/12 
0/27 
20 
24 
18 
18 
27 
57 
11 
11 
4 
0 
54 
2 
1 
0 
0 
HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; AH, acute hepatitis; NC, 
normal control. 
Table 5. Patients’ data in the present study 
The levels of circulating HIF-1ǂ expression in 220 patients with liver diseases are shown in 
Table 6. The circulating HIF-1ǂ level was increased, especially in patients with chronic liver 
diseases. If the cutoff value of serum HIF-1ǂ level was >50 μg/L, the incidence of HIF-1ǂ 
abnormality was 100 % in HCC, 89.2% in LC, 66.7 % in CH, none in AH or NC, respectively; 
And the cutoff values rise to 100 μg/L, the abnormality of circulating HIF-1ǂ level was 
90.8% in HCC and 27.0% in LC, none in CH or AH or NC, respectively. The level of serum 
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HIF-1ǂ in HCC patients was significantly higher (P < 0.001) than those in cases with benign 
liver diseases.  
The prognosis of HCC is poor, and early detection is of the utmost importance. Treatment 
options are severely limited by the frequent presence of metastases. Although the 
mechanisms of hepatocarcinogenesis have not been elucidated, a long-lasting inflammation 
induced by hepatitis virus infection is a definite risk for neoplastic degeneration and 
accumulation of genetic alterations. The fragments of circulating HIF-1ǂ could be detected 
in all patients with HCC with extrahepatic metastasis; like circulating IGF-II, these results 
argue for growth factor–dependent HCC development and could provide novel markers of 
severity and prognosis for HCC. The present data indicate that the expression levels of 
serum HIF-1ǂ, Ang-2, and VEGF could be detected only in the peripheral blood of patients 
with HCC. 
 
Group n 
HIF-1ǂ (μg/L) >50 μg/L 
n (%) 
>100 μg/L 
n (%) 
Ranges                  Mean ± SD 
HCC  
LC 
CH 
AH 
NC  
131 
37 
30 
22 
27 
57.5~208.5 
39.1~123.4 
38.0~96.4 
33.1~48.8 
20.3~31.9 
136.3 ± 28.8 
84.6 ± 25.9* 
58.8 ± 14.5*a 
37.6 ± 5.3*bc 
24.1 ± 3.3*de 
131(100) 
33(89.2) 
20(66.7)* 
0(0)* 
0(0)* 
119(90.8) 
10(27.0)* 
0(0)* 
0(0)* 
0(0)* 
*P < 0.001, vs the HCC group；aP < 0.001, vs the liver cirrhosis group (q = 4.39)；bP < 0.01 vs the chronic 
hepatitis group (q = 3.17)；cP < 0.001, vs the liver cirrhosis group (q = 7.31)；d P < 0.001, vs the chronic 
hepatitis group (q = 5.47)；eP < 0.001, vs the liver cirrhosis group (q = 9.99)；HCC, hepatocellular 
carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; AH, acute hepatitis; NC, normal control. 
Table 6. Quantitative analysis of circulating HIF-1ǂ level (mean ± SD) in patients with liver 
diseases 
The evaluation of serum HIF-1ǂ and AFP levels for HCC diagnosis using the ROC curves is 
shown in Fig.7. The advantage of analyzing two markers over the whole range of 
sensitivities and specificities using the area (0.854 in AFP, 0.909 in HIF-1ǂ) under ROC 
curves indicated that the abnormality of serum HIF-1ǂ level could be a useful seroloical 
marker for HCC diagnosis. 
5. Quantitative detection of VEGF and Ang-2 
The levels of serum VEGF and Ang-2 were detected and the concentrations were calculated 
using a standard curve generated with specific standards. Inter and intra-assay variances 
were lower than 10%. The levels of circulating VEGF and Ang-2 expression in patients with 
chronic liver diseases are shown in Table 7. Like circulating HIF-1ǂ expression, the 
circulating VEGF and Ang-2 levels were increased in patients with chronic liver diseases, 
especially in HCC patients. If the cutoff value with >280 μg/L for VEGF and >35 μg/L for 
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Ang-2, the incidence of VEGF and Ang-2 were 87.0 % and 94.7 % abnormality in HCC, 12.7 
% and 2.9 % in LC, 13.3 % and 0% in CH, both none in NC, respectively.  
 
 
Fig. 7. The relationship between circulating HIF-1ǂ and AFP levels and receiver operating 
characteristic (ROC) curves. A, the scatter diagram of circulating HIF-1ǂ and AFP levels in 
HCC patients，and no significant relationship was found between circulating HIF-1ǂ and 
AFP levels; B, ROC curves for circulating HIF-1ǂ and AFP investigated markers for HCC. 
Sensitivity = true-positive rate; specificity = false-positive rate; and the area under ROC 
curves was 0.854 for AFP and 0.909 for HIF-1ǂ. Sensitivity and specificity were calculated 
according to the following formulas: Sensitivity = a/(a+c); and Specificity = d/ (b+d), where 
a = true-positive cases, b = false-positive cases, c = false- negative cases, and d = true-
negative cases. ROC curves were constructed by calculating the sensitivities and specificities 
at several cutoff points, and indicated that both of circulating HIF-1ǂ and AFP level be 
useful molecular markers for HCC diagnosis. 
HCC is known to contain aberantly vascularized regions characterized by severe hypoxia. 
Hypoxia can stimulate cell proliferation, induce angiogenesis, accelerate invasion and is also 
responsible for treatment resistance in HCC. Activation of oncogenes or inactivation of 
tumor suppressors can change signaling pathway and up-regulate HIF-1ǂ expression, 
leading to HIF-1ǂ activation. Under hypoxic conditions it can be stabilized, binding to the 
specific sites of hypoxia-response target genes, regulating proliferation on transcriptional 
level and activating expression of many hypoxia-response genes, which are closely relevant 
with energy metabolism, angiogenesis, infiltration, metastasis and prognosis. The frequency 
of circulating HIF-1ǂ and its diagnostic value increased with distal metastases of HCC 
hepatocytes. The pathological characteristics of serum HIF-1ǂ associated with the levels of 
circulating VEGF and Ang-2 expression, the size of tumor and extra-hepatic metastasis, and 
but not to patients’ gender, age, and AFP level. 
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Group n 
 VEGF (μg/L)   >280 μg/L    Ang-2 (μg/L)   >35 μg/L 
Mean ± SD      n (%)       Mean ± SD    n (%) 
HCC 
LC 
CH 
NC 
131 
37 
30 
27 
462.7±119.2   114(87.0)      40.8±3.5    124(94.7) 
216.3±54.5*    6(16.2)*      25.5±5.8*    1(2.7)* 
160.9±98.2*    4(13.3)*      20.9±7.1*     0(0)* 
 140.9±54.5*     0(0)*        17.4±2.6*     0(0)* 
*P < 0.001, vs the HCC group；HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic 
hepatitis; NC, normal control. 
Table 7. The levels of circulating VEGF and Ang-2 expression in patients with chronic liver 
diseases 
6. Clinicopathological features of HIF-1α expression  
The clinicopathological characteristics of circulating HIF-1ǂ expression in HCC patients are 
shown in Table 8. Significant difference was found between high HIF-1ǂ expression and 
tumor size (P=0.007) or HCC with extra-hepatic metastasis (P< 0.001), but not with patients’ 
gender, age, or AFP level. There was a very close relationship between circulating HIF-1ǂ 
level and VEGF (r=0.937, P <0.001) or Ang-2 (r= 0.933, P < 0.001), suggesting that high 
expression of HIF-1ǂ associated with HCC metastasis and poor prognosis. 
Clinical pathological features of HIF-1ǂ expression indicated that HIF-1ǂ expression 
intensity and positive rate was lower in HCC than in paracancerous tissues, which were in 
accordance with total RNA. HIF-1ǂ positive rate was associated with tumor diameter, 
because they were usually singles, enveloped, well-differentiated, more diplonts and less 
heteromorphism when tumors were small. With tumors swelling, the biological 
characteristics have changed, developed into the opposite. Therefore, the invasion is 
strengthened, and tumor blood supply can not satisfy growth demand. HBx and HIF-1ǂ are 
presented in cytoplasm in HCC. Moreover, HBx can up-regulate HIF-1ǂ under normoxia or 
hypoxia, reinforce HIF-1ǂ transcriptional activity via MAPK pathway, increase HIF-1ǂ 
protein levels, induce neovascularization and contribute to metastasis. No correlation was 
found between HIF-1ǂ and HBsAg positive in HCC and further studies whether it 
associates with HBV replication are required. 
7. Effect of miRNA silencing HIF-1α gene on HCC 
In order to investigate the effect of miRNA silencing HIF-1ǂ gene on inhibition of HepG2 
cell proliferation. Recently, we constructed the eukaryotic expression plasmids of HIF-
1ǂmiRNA and report gene containing hypoxia-reponse element. After HepG2 cells 
transfection with plasmid, the expression of HIF-1ǂ gene and protein were determined by 
real time-PCR or Western blotting. The expressions of HIF-1ǂ, VEGF, and Ang-2 were 
quantitatively detected by ELISA. The alterations of cell cycles and apoptosis rate were 
quantitatively measured by flow cytometry or Annexin V-FITC/PI double dyeing assay. 
At 72h After HepG2 cell transfection with HIF-1ǂmiRNA, the down- regulation of HIF-1ǂ 
was 87% at mRNA or 56% at protein level, and the decreasing of target gene was 46% in the 
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report gene, 54% in VEGF and 36% in Ang-2, respectively. The apoptotic ratio of HepG2 cells 
was 22.46 ± 0.61% (P < 0.01), and the cell cycle changed greatly at the ratio of G1 
(61.49±1.12%) and S phase (22.40± 0.58%, P < 0.01). After the cells combined with 
doxorubicin, the apoptotic ratio increased to 36.99 ± 0.88%. The ratio of G1 and S phase were 
upregulated to 65.68 ± 0.91% and 19.47 ± 1.34%. HIF-1ǂmiRNA or / and doxorubicin can 
regulate the growth cycle, promote apoptotic and inhibit proliferation of HepG2 cells. 
 
Group          n       HIF-1ǂ(μg/L)           t value  P value      
HCC 
Sex         Male 
Female 
Age         ≥ 50y 
<50y 
Tumor size   ≥ 5.0 cm 
<5.0 cm 
AFP(μg/L)   ≥ 400.0 
< 400.0 
HBsAg       Positive 
Negative 
EHT         Yes 
No 
131 
109 
22 
98 
33 
53 
78 
53 
78 
100 
31 
49 
82 
136.3 ± 28.8 
137.4 ± 28.7 
130.7 ± 29.0 
133.7 ± 30.1 
143.2 ± 24.0 
144.4 ± 26.3* 
130.8 ± 29.2 
136.9 ± 25.8 
135.9 ± 30.7 
137.9 ± 29.6 
129.2 ± 25.5 
152.5 ± 21.5** 
126.6 ± 28.3 
 
1.009 
 
1.702 
 
2.721 
 
0.201 
 
1.712 
 
5.522 
 
0.315 
 
0.091 
 
0.007 
 
0.841 
 
0.089 
 
0.000 
*P < 0.01, vs the tumor size less than 5㎝ group; **P < 0.001, vs the non- extrahepatic metastasis group; 
HCC, hepatocellular carcinoma; EHT, Extra- hepatic metastasis. 
Table 8. The pathological characteristics of HIF-1ǂ levels (mean ± SD) in sera of HCC 
patients. 
8. Perspectives 
HCCs exhibit numerous genetic abnormalities as well as epigenetic alterations including 
modulation of DNA methylation (23, 24). Molecular factors are involved in the process of 
HCC development and metastasis (25~27). Recent findings from several laboratories have 
implicated constitutive activation of the transcription factor NFkappa B as one of the early 
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key events involving in neoplastic progression of the liver. Further studies will permit us to 
analyze mechanism of human hepatocarcinogenesis and pay attention to these areas 
(28~31). However, the hepatic HIF-1ǂ expression is associated with development and 
prognosis of HCC, and circulating HIF-1ǂ level is a useful molecular marker in HCC 
diagnosis, and monitor prognosis (32~36). HIF-1ǂ expression in hepatic tissues plays an 
important role in development and prognosis of HCC. HIF-1ǂ, as an initial hypoxia 
moderator, should be a promising molecular-target for the development of anti-HCC agents 
(37~40). The intensity of HIF-1ǂ expressions was significantly higher in paracancerous 
tissues than in HCC, mainly due to more necrosis in the latter, representing that there is a 
very close relationship between high intensity of HIF-1ǂ expressions and active metabolism 
or hypoxia microenvironment in paracancerous tissues and HIF-1ǂ could be a molecular-
target for gene therapy (41, 42).  
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